Safety and effectiveness of Satinex buccal spray

Phase 2

• Conditions: Multiple Sclerosis.; Multiple sclerosis

• Registration Number: IRCT20200408046986N1
• Lead Sponsor: Yasdaru pharmaceuticals

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Written Informed consent of all patients included in the study
Patients diagnosed with multiple sclerosis by a specialist
Stability of patients disease since one month before the study being started
Patients Disease Modifying Therapy regimen should remain the same during the study

Exclusion Criteria

A history of Schizophrenia and other serious mental morbidities (Except depression and anxiety due to MS disease)
A history of substance abuse
Smoking and generally using cannabis (since 30 days prior to the study starting date and disability to quit during the study ) and taking any other cannabis based medications (60 days prior to study starting date)
taking Botulinum shot since 4 months prior to the study starting date
a history of epilepsy and repetitive convulsions
a history of MI and serious cardiac arrest
acute liver and renal failure
pregnancy and lactation
Taking other investigational drugs
elective surgeries and blood donation

Study & Design

• Study Type: interventional
• Study Design: Not specified